Oragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. The Company is dedicated to the development and commercialization of a vaccine candidate providing specific immunity from novel coronavirus. The Terra CoV-2 immunization leverages coronavirus spike protein research conducted by the National Institute of Health. In addition, Oragenics has an exclusive worldwide channel collaboration with ILH Holdings, Inc. (n/k/a Eleszto Genetika, Inc.), relating to the development of novel lantibiotics.
Company profile
Ticker
OGEN
Exchange
Website
CEO
Alan F. Joslyn
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Noachis Terra Inc. ...
IRS number
593410522
OGEN stock data
Latest filings (excl ownership)
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
17 Apr 23
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
10 Apr 23
8-K
Regulation FD Disclosure
3 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
8-K
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
14 Mar 23
8-K
Oragenics Appoints Janet Huffman as Chief Financial Officer
8 Mar 23
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 9.16 mm | 9.16 mm | 9.16 mm | 9.16 mm | 9.16 mm | 9.16 mm |
| Cash burn (monthly) | 756.15 k | 1.02 mm | 968.27 k | 1.06 mm | 702.90 k | 975.02 k |
| Cash used (since last report) | 1.65 mm | 2.22 mm | 2.11 mm | 2.31 mm | 1.53 mm | 2.12 mm |
| Cash remaining | 7.51 mm | 6.94 mm | 7.05 mm | 6.85 mm | 7.63 mm | 7.03 mm |
| Runway (months of cash) | 9.9 | 6.8 | 7.3 | 6.5 | 10.9 | 7.2 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 31 |
| Opened positions | 11 |
| Closed positions | 7 |
| Increased positions | 4 |
| Reduced positions | 8 |
| 13F shares | Current |
|---|---|
| Total value | 959.89 mm |
| Total shares | 11.75 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 5.06 mm | $532.14 mm |
| Intracoastal Capital | 1.49 mm | $670.00 k |
| BLK Blackrock | 1.33 mm | $139.80 mm |
| Sara-Bay Financial | 1.27 mm | $134.00 mm |
| Geode Capital Management | 747.03 k | $78.00 k |
| STT State Street | 495.56 k | $52.08 mm |
| Renaissance Technologies | 288.40 k | $30.00 k |
| NTRS Northern Trust | 181.38 k | $19.06 mm |
| FMR | 155.81 k | $16.38 mm |
| Susquehanna International | 146.95 k | $15.45 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Mar 23 | Janet Huffman | Employee Option Common Stock | Grant | Acquire A | No | No | 4 | 7,000 | 28.00 k | 7,000 |
| 30 Dec 22 | Robert C Koski | Common Stock | Sell | Dispose S | Yes | No | 0.1055 | 42,357 | 4.47 k | 1,102,295 |
| 29 Dec 22 | Robert C Koski | Common Stock | Sell | Dispose S | No | No | 0.106 | 36,648 | 3.88 k | 176,191 |
| 15 Dec 22 | Robert C Koski | Common Stock | Sell | Dispose S | Yes | No | 0.1758 | 140,497 | 24.70 k | 1,144,652 |
| 14 Dec 22 | Robert C Koski | Common Stock | Sell | Dispose S | Yes | No | 0.175 | 4,503 | 788.03 | 1,310,149 |
| 14 Dec 22 | Robert C Koski | Common Stock | Sell | Dispose S | Yes | No | 0.175 | 25,000 | 4.38 k | 1,285,149 |
News
Stocks That Hit 52-Week Lows On Monday
27 Mar 23
Stocks That Hit 52-Week Lows On Friday
24 Mar 23
Stocks That Hit 52-Week Lows On Thursday
23 Mar 23
Oragenics Reports Findings From Third Party Laboratory Testing Of Several Compounds In Oragenics' Lantibiotics Platform To Combat Multiple Pathogens Resistant To Standard-of-care Antibiotics
14 Mar 23
Stocks That Hit 52-Week Lows On Wednesday
8 Mar 23